SCHEMBL4193311

SCHEMBL4193311

CCCCN(CC)CCNC(=O)Cc1ccc2c(c1)C(N)C(O)C(C)(C)O2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ TRPV1 Q8NER1 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KCNE1 P15382 1/20 0.35
▸ KCNQ1 P51787 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ ACKR3 P25106 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193309 1.00 KCNA5 (0.40) KCNA5ALDH1A1TRPV1CA1CA2
SCHEMBL4470956 0.88 CA1 (0.47) KCNA5TRPV1CA1CA2HPGD
SCHEMBL4188574 0.84 KCNA5 (0.37) KCNA5ALDH1A1TRPV1CA1CA2
SCHEMBL4188577 0.84 KCNA5 (0.37) KCNA5ALDH1A1TRPV1CA1CA2
SCHEMBL4193314 0.81 TRPV1 (0.37) KCNA5TRPV1CA1CA2HPGD
SCHEMBL4186208 0.77 KCNA5 (0.49) KCNA5MEN1KMT2AGAAKCNE1
SCHEMBL4490339 0.76 NPC1 (0.46) KCNA5ALDH1A1CA1CA2LMNA
SCHEMBL4192886 0.76 CYP2D6 (0.47) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL4192882 0.76 CYP2D6 (0.47) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL4185887 0.73 ACKR3 (0.42) KCNA5ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273905-B2 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives ABBOTT PRODUCTS GMBH (DE) 2012-09-25 — — US disclosed
US-20090203686-A1 Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives SOLVAY PHARMACEUTICALS GMBH (DE) 2009-08-13 — — US disclosed
EP-1871758-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS Solvay Pharmaceuticals GmbH (DE) 2008-01-02 — — EP disclosed
US-20060252821-A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives SOLVAY PHARMACEUTICALS GMBH 2006-11-09 — — US disclosed
WO-2006108837-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS SOLVAY PHARMACEUTICALS GMBH (DE) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252821-A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 KCNA5 929/4885ALDH1A1 737/4885TRPV1 2919/4885
US-20090203686-A1 Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 KCNA5 1080/4885ALDH1A1 681/4885TRPV1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback